Christopher Dewey Net Worth

The estimated Net Worth of Christopher C Dewey is at least $332 Mille dollars as of 31 March 2020. Mr. Dewey owns over 6,611 units of MYOS RENS Technology stock worth over $332,272 and over the last 5 years he sold MYOS stock worth over $0. In addition, he makes $0 as Independent Director at MYOS RENS Technology.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Mr. Dewey MYOS stock SEC Form 4 insiders trading

Christopher has made over 2 trades of the MYOS RENS Technology stock since 2020, according to the Form 4 filled with the SEC. Most recently he bought 6,611 units of MYOS stock worth $6,677 on 31 March 2020.

The largest trade he's ever made was buying 82,645 units of MYOS RENS Technology stock on 5 March 2020 worth over $100,000. On average, Christopher trades about 44,628 units every 13 days since 2020. As of 31 March 2020 he still owns at least 328,982 units of MYOS RENS Technology stock.

You can see the complete history of Mr. Dewey stock trades at the bottom of the page.

Christopher Dewey biography

Christopher C. Dewey serves as Independent Director of the Company. From January 2007 to April 2011, he served as Vice Chairman of the board of directors of National Holdings Corporation, a financial services organization operating through its subsidiary, National Securities. From December 2006 to December 2008, Mr. Dewey served as acting Chief Executive Officer and director of Z-KAT, Inc., a surgical navigation medical device company. He previously served as Executive Vice President of Jefferies & Company, Inc., the principal operating subsidiary of Jeffries Group, Inc., a securities and investment banking firm, from 1994 to December 2006. Mr. Dewey co-founded several companies, including Robotic Ventures LLC, Bonds Direct Securities LLC and Cannon Group Inc., a motion picture company that went public in 1972. Mr. Dewey has also served on the board of directors of various companies including Orthosensor, Inc., a medical device company, Mako Surgical Corp., a medical device company, and Auris Surgical Robotics, Inc., an ophthalmic robotics company. Mr. Dewey holds an M.B.A. from The Wharton School of the University of Pennsylvania.

How old is Christopher Dewey?

Christopher Dewey is 75, he's been the Independent Director of MYOS RENS Technology since 2019. There are no older and 7 younger executives at MYOS RENS Technology.

What's Christopher Dewey's mailing address?

Christopher's mailing address filed with the SEC is C/O MYOS RENS TECHNOLOGY INC., 45 HORSEHILL ROAD, SUITE 106, CEDAR KNOLLS, NJ, 07927.

Insiders trading at MYOS RENS Technology

Over the last 12 years, insiders at MYOS RENS Technology have traded over $0 worth of MYOS RENS Technology stock and bought 2,115,845 units worth $2,654,259 . The most active insiders traders include David J Matlin, Christopher Pechock e Joseph Mannello. On average, MYOS RENS Technology executives and independent directors trade stock every 78 days with the average trade being worth of $59,361. The most recent stock trade was executed by Joseph Mannello on 31 March 2020, trading 16,529 units of MYOS stock currently worth $16,694.

What does MYOS RENS Technology do?

MYOS RENS Technology, Inc. operates as a nutrition company, develops and markets products that improve muscle health and performance. Its primary product is Fortetropin, a proprietary bioactive composition derived from fertilized egg yolk, intended to increase lean muscle mass, size, and strength. The company was founded on April 11, 2007 and is headquartered in Cedar Knolls, NJ.

Complete history of Mr. Dewey stock trades at MYOS RENS Technology

MYOS RENS Technology executives and stock owners

MYOS RENS Technology executives and other stock owners filed with the SEC include:

• Joseph Mannello,
  Chief Executive Officer, Director
• Robert Hariri,
  Independent Chairman of the Board
• Eric Zaltas,
  Independent Director
• Andrew Ponte,
  Independent Director
• Christopher Pechock,
  Independent Director
• Victor Mandel,
  Independent Director
• Christopher Dewey,
  Independent Director
• Louis Aronne,
  Independent Director
• Ren Ren,
  Director
• Sapna Srivastava,
  Director
• Joseph Dos Santos,
  Chief Financial Officer
• Kenrick Bryce Toussaint,
  Chief Executive Officer
• Buzz Aldrin,
  Director
• Zhengguang Lyu,
  Director
• Robert C. Jr. Ashton,
  Chief Medical Officer
• Peter Diamandis,
  Director
• John Craig Venter,
  Director
• Peter Levy,
  COO & Executive VP
• John Nosta,
  Director
• Carl De Freitas,
  Interim CFO
• Glen R. Fleischer,
  Chief Executive Officer
• David J Matlin,
  10% owner